Literature DB >> 26791236

Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?

M Pietilä1, J Ivaska1, S A Mani2.   

Abstract

Changes in the tumor microenvironment (TME) can trigger the activation of otherwise non-malignant cells to become highly aggressive and motile. This is evident during initial tumor growth when the poor vascularization in tumors generates hypoxic regions that trigger the latent embryonic program, epithelial-to-mesenchymal transition (EMT), in epithelial carcinoma cells (e-cars) leading to highly motile mesenchymal-like carcinoma cells (m-cars), which also acquire cancer stem cell properties. After that, specific bidirectional interactions take place between m-cars and the cellular components of TME at different stages of metastasis. These interactions include several vicious positive feedback loops in which m-cars trigger a phenotypic switch, causing normal stromal cells to become pro-tumorigenic, which then further promote the survival, motility, and proliferation of m-cars. Accordingly, there is not a single culprit accounting for metastasis. Instead both m-cars and the TME dynamically interact, evolve and promote metastasis. In this review, we discuss the current status of the known interactions between m-cars and the TME during different stages of metastasis and how these interactions promote the metastatic activity of highly malignant m-cars by promoting their invasive mesenchymal phenotype and CSC properties.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Epithelial-to-mesenchymal transition; Immune modulation; Metastasis; Tumor microenvironment; Tumor stroma

Mesh:

Year:  2016        PMID: 26791236     DOI: 10.1016/j.canlet.2015.12.033

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Toward understanding cancer stem cell heterogeneity in the tumor microenvironment.

Authors:  Federico Bocci; Larisa Gearhart-Serna; Marcelo Boareto; Mariana Ribeiro; Eshel Ben-Jacob; Gayathri R Devi; Herbert Levine; José Nelson Onuchic; Mohit Kumar Jolly
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-26       Impact factor: 11.205

Review 2.  The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

Authors:  Marina De Rosa; Daniela Rega; Valeria Costabile; Francesca Duraturo; Antonello Niglio; Paola Izzo; Ugo Pace; Paolo Delrio
Journal:  Therap Adv Gastroenterol       Date:  2016-08-07       Impact factor: 4.409

3.  Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice.

Authors:  Dasha Fuentes; Alejandro Cabezas-Cruz; Circe Mesa; Tania Carmenate; Darel Martínez; Anet Valdés-Zayas; Enrique Montero; Rolando Pérez
Journal:  J Breast Cancer       Date:  2022-04-26       Impact factor: 2.922

4.  PTP1B promotes aggressiveness of breast cancer cells by regulating PTEN but not EMT.

Authors:  Xue Liu; Qian Chen; Xu-Gang Hu; Xian-Chao Zhang; Ti-Wei Fu; Qing Liu; Yan Liang; Xi-Long Zhao; Xia Zhang; Yi-Fang Ping; Xiu-Wu Bian
Journal:  Tumour Biol       Date:  2016-07-27

5.  Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

Authors:  Ila Datar; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2016-04-13       Impact factor: 12.531

Review 6.  Recent advances in understanding the complexities of metastasis.

Authors:  Jessica L Chitty; Elysse C Filipe; Morghan C Lucas; David Herrmann; Thomas R Cox; Paul Timpson
Journal:  F1000Res       Date:  2018-08-01

7.  Shikonin blocks human lung adenocarcinoma cell migration and invasion in the inflammatory microenvironment via the IL‑6/STAT3 signaling pathway.

Authors:  Tao Pan; Fang Zhang; Fakai Li; Xingchun Gao; Zhikui Li; Xia Li; Xinling Ren
Journal:  Oncol Rep       Date:  2020-07-09       Impact factor: 3.906

8.  Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.

Authors:  Emmanuel Zervos; Steven Agle; Andrew G Freistaedter; Gwendolyn J B Jones; Rachel L Roper
Journal:  J Exp Clin Cancer Res       Date:  2016-03-01

Review 9.  Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.

Authors:  Ana Cavaco; Maryam Rezaei; Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923

Review 10.  Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis.

Authors:  Xiao Yang; Xinhua Liang; Min Zheng; Yaling Tang
Journal:  Front Oncol       Date:  2018-11-05       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.